Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of familial adenomatous polyposis (FAP) based on genetic predisposition testing~* Genotype-positive FAP (pathologic Adenomatous polyposis coli (APC) mutation)~  * No attenuated FAP genotype, defined by any of the following:~    * Mutation at the 5' end of APC and exon 4~   * Exon 9-associated phenotypes~   * 3' region mutations~* Has an intact colon~  * No requirement for colectomy~ * Parent(s) do not desire colectomy (regardless of adenoma burden)~* Colorectal adenoma burden as assessed by baseline colonoscopy~  * No diagnosis of severe dysplasia or greater~ * No more than 10 adenomas ≥ 1 cm~ * No more than 100 adenomas of any size~ * No evidence of anemia (hematocrit \< 33%)~* No new diagnosis of carcinoma~PATIENT CHARACTERISTICS:~* White Blood Count (WBC) \> 3,000/μL~* Platelet count \> 100,000/μL~* Hemoglobin \> 10.0 g/dL~* Aspartate aminotransferase/alanine aminotransferase (AST/ALT) \< 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase \< 1.5 times ULN~* Total bilirubin \< 1.5 times ULN~* Creatinine \< 1.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No history of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAIDs, or salicylates~* No history of peptic ulcer disease~* No significant medical or psychiatric problem that, in the opinion of the principal investigator, would make the patient a poor candidate for the study~* No other unacceptable clinical risk (e.g., previously unknown bleeding diatheses)~* No invasive carcinoma within the past 5 years~PRIOR CONCURRENT THERAPY:~* More than 3 months since prior investigational agent~* More than 6 months since prior chemotherapy~* No prior radiotherapy to the pelvis~* At least 3 months since prior NSAIDs (at any dose) at a frequency of ≥ 3 times/week~* At least 1 month since prior NSAIDs (at any dose) at a frequency of \< 3 times/week~* At least 1 month since prior nasal steroids~* Concurrent Nonsteroidal Antiinflammatory Drugs (NSAIDs) allowed provided they are administered ≤ 5 times per month~* Concurrent orally inhaled steroids allowed provided they are administered for ≤ 4 weeks over a 6-month period~* Concurrent oral or intravenous (IV) corticosteroids allowed provided they are administered for ≤ 2 consecutive weeks over a 6-month period~* Concurrent proton pump inhibitors to treat gastric reflux allowed~* No concurrent nasal steroids except mometasone (Nasonex)~* No concurrent fluconazole, lithium, or adrenocorticosteroids

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral celecoxib twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive oral placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).